Gene therapy in transplantation: Toward clinical trials

Current Opinion in Molecular Therapeutics

Volumn 11, Issue 5, 2009, Pages 504-512

  Ritter, T ^a   Nosov, M ^a   Griffin, M D ^a  

^a NATIONAL UNIVERSITY OF IRELAND   (Ireland)

Author keywords

Allograft rejection; Clinical trial; Gene therapy; Immune tolerance; Transplantation; Viral vector

Indexed keywords

ADENOVIRUS VECTOR; ANTIVIRUS AGENT; BAG 1 PROTEIN; BELATECEPT; CYCLOSPORIN; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; FIBROBLAST GROWTH FACTOR 1; GANCICLOVIR; GLUCURONOSYLTRANSFERASE; HERPESVIRUS VECTOR; HYPOXIA INDUCIBLE FACTOR 1ALPHA; IMMUNOGLOBULIN; IMMUNOSUPPRESSIVE AGENT; INTERLEUKIN 10; LENTIVIRUS VECTOR; LOW DENSITY LIPOPROTEIN RECEPTOR; PARVOVIRUS VECTOR; PROTEIN BCL 2; PROTEIN BCL XL; QPI 1002; RETROVIRUS VECTOR; SCATTER FACTOR; SMALL INTERFERING RNA; THYMIDINE KINASE; TRANSCRIPTION FACTOR FOXP3; TRANSFORMING GROWTH FACTOR BETA; UNCLASSIFIED DRUG; VASCULOTROPIN; VIRUS ANTIGEN;

ACUTE GRAFT REJECTION; ALLOTRANSPLANTATION; CHRONIC GRAFT REJECTION; CLINICAL TRIAL; CRIGLER NAJJAR SYNDROME; CYTOMEGALOVIRUS INFECTION; DELAYED GRAFT FUNCTION; DENDRITIC CELL; DNA MODIFICATION; DRUG EFFECT; DRUG SAFETY; EX VIVO GENE TRANSFER; GENE THERAPY; GRAFT REJECTION; GRAFT SURVIVAL; HUMAN; HYPERCHOLESTEROLEMIA; IMMUNOLOGICAL TOLERANCE; ISCHEMIA; LIVER CELL CARCINOMA; NONHUMAN; REPERFUSION INJURY; REVIEW; T LYMPHOCYTE; VIRUS INFECTION;

ANIMALS; CLINICAL TRIALS AS TOPIC; GENE THERAPY; GENE TRANSFER TECHNIQUES; HUMANS; MODELS, ANIMAL; TRANSPLANTATION;

EID: 70349900807     PISSN: 14648431     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (74)

1. Meier-Kriesche HU, Schold JD, Srinivas TR, Kaplan B: Lack of improvement in renal allograft survival despite a marked decrease in acute rejection rates over the most recent era. Am J Transplant (2004) 4(3):378-383.
2. Halloran PF: Immunosuppressive drugs for kidney transplantation. N Engl J Med (2004) 351(26):2715-2729.
3. Goldman M, Wood K: Translating transplantation tolerance in the clinic: Where are we, where do we go? Clin Exp Immunol (2009) 156(2):185-188.
4. Cavazzana-Calvo M, Hacein-Bey S, de Saint Basile G, Gross F, Yvon E, Nusbaum P, Selz F, Hue C, Certain S, Casanova JL, Bousso P et al: Gene therapy of human severe combined immunodeficiency (SCID)-X1 disease. Science (2000) 288(5466):669-672. •• Describes the first gene therapy trial for SCID-X1 using a replication-defective Moloney retrovirus-derived vector. Gene therapy corrected the disease phenotype and resulted in clinical benefit.
5. Brantly ML, Spencer LT, Humphries M, Conlon TJ, Spencer CT, Poirier A, Garlington W, Baker D, Song S, Berns KI, Muzyczka N et al: Phase I trial of intramuscular injection of a recombinant adeno-associated virus serotype 2 α1-antitrypsin (AAT) vector in AAT-deficient adults. Hum Gene Ther (2006) 17(12):1177-1186. (Pubitemid 44975135)
6. Aiuti A, Cattaneo F, Galimberti S, Benninghoff U, Cassani B, Callegaro L, Scaramuzza S, Andolfi G, Mirolo M, Brigida I, Tabucchi A et al: Gene therapy for immunodeficiency due to adenosine deaminase deficiency. N Engl J Med (2009) 360(5):447-458.
7. Bainbridge JW, Smith AJ, Barker SS, Robbie S, Henderson R, Balaggan K, Viswanathan A, Holder GE, Stockman A, Tyler N, Petersen-Jones S et al: Effect of gene therapy on visual function in Leber's congenital amaurosis. N Engl J Med (2008) 358(21):2231-2239. • Recent important article on the treatment of three patients with loss of vision with AAV-mediated gene transfer of RPE65.
8. Kay MA, Glorioso JC, Naldini L: Viral vectors for gene therapy: The art of turning infectious agents into vehicles of therapeutics. Nat Med (2001) 7(1):33-40.
9. Edelstein ML, Abedi MR, Wixon J: Gene therapy clinical trials worldwide to 2007 - An update. J Gene Med (2007) 9(10):833-842.
10. Wilson JM: Lessons learned from the gene therapy trial for ornithine transcarbamylase deficiency. Mol Genet Metab (2009) 96(4):151-157.
11. ClinicalTrials.gov: NIH, Bathesda, MA, USA (2009). www.clinicaltrials.gov
12. Baum C, Kustikova O, Modlich U, Li Z, Fehse B: Mutagenesis and oncogenesis by chromosomal insertion of gene transfer vectors. Hum Gene Ther (2006) 17(3):253-263.
13. Montini E, Cesana D, Schmidt M, Sanvito F, Bartholomae CC, Ranzani M, Benedicenti F, Sergi LS, Ambrosi A, Ponzoni M, Doglioni C et al: The genotoxic potential of retroviral vectors is strongly modulated by vector design and integration site selection in a mouse model of HSC gene therapy. J Clin Invest (2009) 119(4):964-975.
14. Daya S, Berns KI: Gene therapy using adeno-associated virus vectors. Clin Microbiol Rev (2008) 21(4):583-593.
15. Kay MA, Manno CS, Ragni MV, Larson PJ, Couto LB, McClelland A, Glader B, Chew AJ, Tai SJ, Herzog RW, Arruda V et al: Evidence for gene transfer and expression of Factor IX in haemophilia B patients treated with an AAV vector. Nat Genet (2000) 24(3):257-261. (Pubitemid 30132193)
16. Stedman H, Wilson JM, Finke R, Kleckner AL, Mendell J: Phase I clinical trial utilizing gene therapy for limb girdle muscular dystrophy: α-, β-, γ-, or δ-Sarcoglycan gene delivered with intramuscular instillations of adeno-associated vectors. Hum Gene Ther (2000) 11(5):777-790. (Pubitemid 30180282)
17. Wagner JA, Messner AH, Moran ML, Daifuku R, Kouyama K, Desch JK, Manley S, Norbash AM, Conrad CK, Friborg S, Reynolds T et al: Safety and biological efficacy of an adeno-associated virus vector-cystic fibrosis transmembrane regulator (AAV-CFTR) in the cystic fibrosis maxillary sinus. Laryngoscope (1999) 109(2 Pt 1):266-274. (Pubitemid 29075570)
18. Lavigne MD, Gorecki DC: Emerging vectors and targeting methods for nonviral gene therapy. Expert Opin Emerg Drugs (2006) 11(3):541-557. (Pubitemid 44386375)
19. Game DS, Lechler RI: Pathways of allorecognition: Implications for transplantation tolerance. Transpl Immunol (2002) 10(2-3):101-108.
20. Gökmen MR, Lombardi G, Lechler RI: The importance of the indirect pathway of allorecognition in clinical transplantation. Curr Opin Immunol (2008) 20(5):568-574.
21. Jevnikar AM, Mannon RB: Late kidney allograft loss: What we know about it, and what we can do about it. Clin J Am Soc Nephrol (2008) 3(Suppl 2):S56-S67.
22. Pleyer U, Ritter T: Gene therapy in immune-mediated diseases of the eye. Prog Retin Eye Res (2003) 22(3):277-293. (Pubitemid 38352549)
23. Clarkson MR, Sayegh MH: T-cell costimulatory pathways in allograft rejection and tolerance. Transplantation (2005) 80(5):555-563. (Pubitemid 41377737)
24. Larsen CP, Pearson TC, Adams AB, Tso P, Shirasugi N, Strobertm E, Anderson D, Cowan S, Price K, Naemura J, Emswiler J et al: Rational development of LEA29Y (belatacept), a high-affinity variant of CTLA4-Ig with potent immunosuppressive properties. Am J Transplant (2005) 5(3):443-453. (Pubitemid 40313335)
25. Miao G, Ito T, Uchikoshi F, Akamaru Y, Kiyomoto T, Komodo H, Song J, Nozawa M, Matsuda H: Development of donor-specific immunoregulatory T-cells after local CTLA4Ig gene transfer to pancreatic allograft. Transplantation (2004) 78(1):59-64. (Pubitemid 38938284)
26. Wei L, Wei-Min L, Cheng G, Bao-Guo Z: Upregulation of CD4+CD25+ T lymphocyte by adenovirus-mediated gene transfer of CTLA4Ig fusion protein in experimental autoimmune myocarditis. Autoimmunity (2006) 39(4):289-298. (Pubitemid 44207825)
27. Harada H, Salama AD, Sho M, Izawa A, Sandner SE, Ito T, Akiba H, Yagita H, Sharpe AH, Freeman GJ, Sayegh MH: The role of the ICOS-B7h T cell costimulatory pathway in transplantation immunity. J Clin Invest (2003) 112(2):234-243. (Pubitemid 38056359)
28. Keir ME, Liang SC, Guleria I, Latchman YE, Qipo A, Albacker LA, Koulmanda M, Freeman GJ, Sayegh MH, Sharpe AH: Tissue expression of PD-L1 mediates peripheral T cell tolerance. J Exp Med (2006) 203(4):883-895.
29. Yamada A, Salama AD, Sayegh MH: The role of novel T cell costimulatory pathways in autoimmunity and transplantation. J Am Soc Nephrol (2002) 13(2):559-575. (Pubitemid 34106301)
30. de Waal Malefyt R, Haanen J, Spits H, Roncarolo MG, te Velde A, Figdor C, Johnson K, Kastelein R, Yssel H, de Vries JE: Interleukin 10 (IL-10) and viral IL-10 strongly reduce antigen-specific human T cell proliferation by diminishing the antigen-presenting capacity of monocytes via downregulation of class II major histocompatibility complex expression. J Exp Med (1991) 174(4):915-924.
31. DeBruyne LA, Li K, Chan SY, Qin L, Bishop DK, Bromberg JS: Lipid-mediated gene transfer of viral IL-10 prolongs vascularized cardiac allograft survival by inhibiting donor-specific cellular and humoral immune responses. Gene Ther (1998) 5(8):1079-1087. (Pubitemid 28401310)
32. David A, Chétritt J, Guillot C, Tesson L, Heslan JM, Cuturi MC, Soulillou JP, Anegon I: Interleukin-10 produced by recombinant adenovirus prolongs survival of cardiac allografts in rats. Gene Ther (2000) 7(6):505-510. (Pubitemid 30156565)
33. Li MC, He SH: IL-10 and its related cytokines for treatment of inflammatory bowel disease. World J Gastroenterol (2004) 10(5):620-625. (Pubitemid 38351523)
34. Maathuis MH, Leuvenink HG, Ploeg RJ: Perspectives in organ preservation. Transplantation (2007) 83(10):1289-1298.
35. Ritter T, Kupiec-Weglinski JW: Gene therapy for the prevention of ischemia/reperfusion injury in organ transplantation. Curr Gene Ther (2005) 5(1):101-109. (Pubitemid 40246743)
36. Vardanian AJ, Busuttil RW, Kupiec-Weglinski JW: Molecular mediators of liver ischemia and reperfusion injury: A brief review. Mol Med (2008) 14(5-6):337-345. (Pubitemid 351785707)
37. Sawitzki B, Amersi F, Ritter T, Fisser M, Shen XD, Ke B, Busuttil R, Volk HD, Kupiec-Weglinski JW: Upregulation of Bag-1 by ex vivo gene transfer protects rat livers from ischemia/reperfusion injury. Hum Gene Ther (2002) 13(12):1495-1504.
38. Blydt-Hansen TD, Katori M, Lassman C, Ke B, Coito AJ, Iyer S, Buelow R, Ettenger R, Busuttil RW, Kupiec-Weglinski JW: Gene transfer-induced local heme oxygenase-1 overexpression protects rat kidney transplants from ischemia/reperfusion injury. J Am Soc Nephrol (2003) 14(3):745-754. (Pubitemid 36246020)
39. Kim IK, Bedi DS, Denecke C, Ge X, Tullius SG: Impact of innate and adaptive immunity on rejection and tolerance. Transplantation (2008) 86(7):889-894.
40. Shen XD, Ke B, Zhai Y, Gao F, Tsuchihashi S, Lassman CR, Busuttil RW, Kupiec-Weglinski JW: Absence of toll-like receptor 4 (TLR4) signaling in the donor organ reduces ischemia and reperfusion injury in a murine liver transplantation model. Liver Transpl (2007) 13(10):1435-1443. • How TLR4 signaling in the donor organ affected IRI sequel following liver transplantation was analyzed. Disruption of the TLR4 pathway downregulated the early proinflammatory responses and ameliorated hepatic IRI.
41. Ke B, Shen XD, Tsuchihashi S, Gao F, Araujo JA, Busuttil RW, Ritter T, Kupiec-Weglinski JW: Viral interleukin-10 gene transfer prevents liver ischemia-reperfusion injury: Toll-like receptor-4 and heme oxygenase-1 signaling in innate and adaptive immunity. Hum Gene Ther (2007) 18(4):355-366. • Investigation of how Ad-mediated gene transfer of viral IL-10 affected the signaling of TLR4 and heme oxygenase 1 in host innate and adaptive immunity during liver IRI. Overexpression of viral IL-10 in association with depressed TLR4 expression prevented IRI.
42. Lechler R, Ng WF, Steinman RM: Dendritic cells in transplantation - Friend or foe? Immunity (2001) 14(4):357-368. (Pubitemid 32441588)
43. Morelli AE, Thomson AW: Tolerogenic dendritic cells and the quest for transplant tolerance. Nat Rev Immunol (2007) 7(8):610-621. (Pubitemid 47123548)
44. Takayama T, Nishioka Y, Lu L, Lotze MT, Tahara H, Thomson AW: Retroviral delivery of viral interleukin-10 into myeloid dendritic cells markedly inhibits their allostimulatory activity and promotes the induction of T-cell hyporesponsiveness. Transplantation (1998) 66(12):1567-1574. (Pubitemid 29034973)
45. Tibbles LA: Reducing the risk of viral infection in renal transplantation. Transplant Proc (2008) 40(10 Suppl):S48-51.
46. Gottschalk S, Bollard CM, Straathof KC, Louis CU, Savoldo B, Dotti G, Brenner MK, Heslop HE, Rooney CM: T cell therapies. Ernst Schering Found Symp Proc (2006) (4):69-82.
47. Micklethwaite KP, Clancy L, Sandher U, Hansen AM, Blyth E, Antonenas V, Sartor MM, Bradstock KF, Gottlieb DJ: Prophylactic infusion of cytomegalovirus-specific cytotoxic T lymphocytes stimulated with Ad5f35pp65 gene-modified dendritic cells after allogeneic hemopoietic stem cell transplantation. Blood (2008) 112(10):3974-3981. • Important clinical trial report that documented the successful immune reconstitution of anti-CMV cellular immunity in 12 allogeneic hematopoietic stem cell transplant recipients. Participants received donor-derived T-cells generated by ex vivo activation using DCs transduced with Ad encoding the CMVpp65 protein.
48. Hara M, Kingsley CI, Niimi M, Read S, Turvey SE, Bushell AR, Morris PJ, Powrie F, Wood KJ: IL-10 is required for regulatory T cells to mediate tolerance to alloantigens in vivo. J Immunol (2001) 166(6):3789-3796. (Pubitemid 32224903)
49. Hori S, Nomura T, Sakaguchi S: Control of regulatory T cell development by the transcription factor Foxp3. Science (2003) 299(5609):1057-1061. •• Seminal paper in which the retroviral gene transfer of Foxp3 converted naïve T-cells toward a Treg phenotype similar to that of naturally occurring CD4+ Treg, indicating that Foxp3 is a key regulatory gene for the development of Treg.
50. Wildin RS, Smyk-Pearson S, Filipovich AH: Clinical and molecular features of the immunodysregulation, polyendocrinopathy, enteropathy, X linked (IPEX) syndrome. J Med Genet (2002) 39(8):537-545. (Pubitemid 34864555)
51. Brunkow ME, Jeffery EW, Hjerrild KA, Paeper B, Clark LB, Yasayko SA, Wilkinson JE, Galas D, Ziegler SF, Ramsdell F: Disruption of a new forkhead/winged-helix protein, scurfin, results in the fatal lymphoproliferative disorder of the scurfy mouse. Nat Genet (2001) 27(1):68-73. (Pubitemid 32044521)
52. Loser K, Hansen W, Apelt J, Balkow S, Buer J, Beissert S: In vitro-generated regulatory T cells induced by Foxp3-retrovirus infection control murine contact allergy and systemic autoimmunity. Gene Ther (2005) 12(17):1294-1304. (Pubitemid 43084485)
53. Chai JG, Xue SA, Coe D, Addey C, Bartok I, Scott D, Simpson E, Stauss HJ, Hori S, Sakaguchi S, Dyson J: Regulatory T cells, derived from naive CD4+CD25- T cells by in vitro Foxp3 gene transfer, can induce transplantation tolerance. Transplantation (2005) 79(10):1310-1316. (Pubitemid 40734792)
54. Kim YH, Lim DG, Wee YM, Kim JH, Yun CO, Choi MY, Park YH, Kim SC, Han DJ: Viral IL-10 gene transfer prolongs rat islet allograft survival. Cell Transplant (2008) 17(6):609-618.
55. Grossman M, Rader DJ, Muller DW, Kolansky DM, Kozarsky K, Clark BJ 3rd, Stein EA, Lupien PJ, Brewer HB Jr, Raper SE, Wilson JM: A pilot study of ex vivo gene therapy for homozygous familial hypercholesterolaemia. Nat Med (1995) 1(11):1148-1154.
56. Birraux J, Menzel O, Wildhaber B, Jond C, Nguyen TH, Chardot C: A step toward liver gene therapy: Efficient correction of the genetic defect of hepatocytes isolated from a patient with Crigler-Najjar syndrome type 1 with lentiviral vectors. Transplantation (2009) 87(7):1006-1012.
57. Li N, Zhou J, Weng D, Zhang C, Li L, Wang B, Song Y, He Q, Lin D, Chen D, Chen G et al: Adjuvant adenovirus-mediated delivery of herpes simplex virus thymidine kinase administration improves outcome of liver transplantation in patients with advanced hepatocellular carcinoma. Clin Cancer Res (2007) 13(19):5847-5854. •• Report of a controlled clinical trial that represents an important milestone in the application of Ad gene therapy to liver transplant recipients. Patients with hepatocellular carcinomas conventionally considered too large for transplantation achieved acceptable patient and graft survival following adjuvant therapy with Ad-encoded thymidine kinase and post-operative ganciclovir.
58. Sandovici M, Deelman LE, de Zeeuw D, van Goor H, Henning RH: Immune modulation and graft protection by gene therapy in kidney transplantation. Eur J Pharmacol (2008) 585(2-3):261-269.
59. Groth CG, Brent LB, Calne RY, Dausset JB, Good RA, Murray JE, Shumway NE, Schwartz RS, Starzl TE, Terasaki PI, Thomas ED, van Rood JJ: Historic landmarks in clinical transplantation: Conclusions from the consensus conference at the University of California, Los Angeles. World J Surg (2000) 24(7):834-843.
60. ISRCTN register: Springer Science and Business Media, Berlin, Germany (2009). isrctn.org
61. International clinical trials registry platform (ICTRP): WHO, Geneva, Switzerland (2009). www.who.int/ictrp/en
62. Current controlled trials: Springer Science and Business Media, Berlin, Germany (2009). www.controlled-trials.com/mrct
63. Our products: QPI-1002 for DGF: Quark Pharmaceuticals Inc, Fremont, CA, USA (2007). www.quarkpharma.com/qbi-en/products/QPI-1002DGF
64. Henry SD, van der Wegen P, Metselaar HJ, Scholte BJ, Tilanus HW, van der Laan LJ: Hydroxyethyl starch-based preservation solutions enhance gene therapy vector delivery under hypothermic conditions. Liver Transpl (2008) 14(12):1708-1717.
65. Bollard CM, Gottschalk S, Leen AM, Weiss H, Straathof KC, Carrum G, Khalil M, Wu MF, Huls MH, Chang CC, Gresik MV et al: Complete responses of relapsed lymphoma following genetic modification of tumor-antigen presenting cells and T-lymphocyte transfer. Blood (2007) 110(8):2838-2845. (Pubitemid 350006936)
66. Stewart DJ, Hilton JD, Arnold JM, Gregoire J, Rivard A, Archer SL, Charbonneau F, Cohen E, Curtis M, Buller CE, Mendelsohn FO et al: Angiogenic gene therapy in patients with nonrevascularizable ischemic heart disease: A phase 2 randomized, controlled trial of AdVEGF121 (AdVEGF121) versus maximum medical treatment. Gene Ther (2006) 13(21):1503-1511. (Pubitemid 44574158)
67. Powell RJ, Simons M, Mendelsohn FO, Daniel G, Henry TD, Koga M, Morishita R, Annex BH: Results of a double-blind, placebo-controlled study to assess the safety of intramuscular injection of hepatocyte growth factor plasmid to improve limb perfusion in patients with critical limb ischemia. Circulation (2008) 118(1):58-65.
68. Grines CL, Watkins MW, Mahmarian JJ, Iskandrian AE, Rade JJ, Marrott P, Pratt C, Kleiman N: A randomized, double-blind, placebo-controlled trial of Ad5FGF-4 gene therapy and its effect on myocardial perfusion in patients with stable angina. J Am Coll Cardiol (2003) 42(8):1339-1347. (Pubitemid 37267270)
69. Nikol S, Baumgartner I, Van Belle E, Diehm C, Visoná A, Capogrossi MC, Ferreira-Maldent N, Gallino A, Wyatt MG, Wijesinghe LD, Fusari M et al: Therapeutic angiogenesis with intramuscular NV1FGF improves amputation-free survival in patients with critical limb ischemia. Mol Ther (2008) 16(5):972-978. (Pubitemid 351587109)
70. Rajagopalan S, Olin J, Deitcher S, Pieczek A, Laird J, Grossman PM, Goldman CK, McEllin K, Kelly R, Chronos N: Use of a constitutively active hypoxia-inducible factor-1α transgene as a therapeutic strategy in no-option critical limb ischemia patients: Phase I dose-escalation experience. Circulation (2007) 115(10):1234-1243. (Pubitemid 46594767)
71. Kochanek S, Clemens PR, Mitani K, Chen HH, Chan S, Caskey CT: A new adenoviral vector: Replacement of all viral coding sequences with 28 kb of DNA independently expressing both full-length dystrophin and β-galactosidase. Proc Natl Acad Sci USA (1996) 93(12):5731-5736. (Pubitemid 126585549)
72. Palmer D, Ng P: Improved system for helper-dependent adenoviral vector production. Mol Ther (2003) 8(5):846-852. (Pubitemid 37527461)
73. Barcia C, Jimenez-Dalmaroni M, Kroeger KM, Puntel M, Rapaport AJ, Larocque D, King GD, Johnson SA, Liu C, Xiong W, Candolfi M et al: One-year expression from high-capacity adenoviral vectors in the brains of animals with pre-existing anti-adenoviral immunity: Clinical implications. Mol Ther (2007) 15(12):2154-2163. (Pubitemid 350148932)
74. Yánez-Muñoz RJ, Balaggan KS, MacNeil A, Howe SJ, Schmidt M, Smith AJ, Buch P, MacLaren RE, Anderson PN, Barker SE, Duran Y et al: Effective gene therapy with nonintegrating lentiviral vectors. Nat Med (2006) 12(3):348-353. (Pubitemid 43355085)